Deciphering CCR8 Activation and Inhibition Mechanisms: Genentech's Findings in Nature Communications.

Recently, a collaborative research effort involving multiple German scientific institutions has revealed that the endothelin B receptor (ETB) plays a crucial role in controlling metabolic syndrome brought on by high-calorie diets.

In January, Oricell Therapeutics announced U.S. FDA approval for the IND application of OriCAR-017 to treat relapsed/refractory multiple myeloma (R/R MM).

Domain Therapeutics secured nearly €10M from the French National Research Agency via the "Hospital-University Health Research SPRINT Alliance" in January, to advance precision medicine and bring their lead drug DT-7012 to clinical trials.

In investigating obesity treatment, the GLP-1 receptor, key for managing Type 2 diabetes and heart disease, is a major focus.

Islet Amyloid Polypeptide (IAPP), also known as amylin, is a peptide hormone composed of 37 amino acids, secreted by the pancreatic beta-cells.

AbbVie, a US-based pharma company, partnered with French firm OSE Immunotherapeutics on Feb 28 to co-develop OSE-230, a new monoclonal antibody for chronic inflammation.

FXR agonists are drugs that activate the farnesoid X receptor, regulating bile acid synthesis and aiding in the treatment of liver and metabolic disorders.

TLR9 agonists are molecules that activate the Toll-like receptor 9, enhancing immune response against microbial infections.

D2 receptor antagonists are drugs that block the D2 subtype of dopamine receptors, used in treating conditions like schizophrenia and bipolar disorder.

5-HT3 receptor antagonists are drugs that block serotonin receptors, used in managing nausea and vomiting. With ongoing research, these drugs hold promise for future therapeutic applications.

H1 receptor antagonists are drugs that block histamine action, relieving allergic reactions. The future holds potential for advancements in treating allergic and inflammatory disorders.